JenaValve Technology, Inc. IRVINE, Calif. and CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

The Heart Valve Devices Market is valued at USD 12.18 Billion in 2024 and is expected to reach USD 41.88 Billion by 2035 at a ...

“This is the largest series of high-risk patients with symptomatic aortic regurgitation that have been treated with the JenaValve,” Makkar said at the press conference. “The 30-day all-cause ...

The Heart Valve Devices Market is witnessing a transformative phase as cardiovascular diseases (CVDs) continue to top the global mortality chart. With an aging population, lifestyle changes, and ...

Written discharge instructions noted no bath and discharge RN remembered instructing the patient, and I remember the hot tub guy asked me if he could use his hot tub and I told him no. Duane Pinto, MD ...

CHICAGO, IL—TAVI using an investigational heart valve system (Trilogy; JenaValve) designed to treat aortic regurgitation (AR) is associated with lower-than-expected mortality and complication rates ...

Completed enrollment in pivotal trials for TaurusNXT (durability-enhanced TAVR), TaurusTrio (aortic regurgitation treatment; the licensed-in JenaValve Trilogy THV System, announced in July 2024 to ...

The study was funded by JenaValve, maker of the Trilogy valve. Makkar will be available to the media in an embargoed press conference on Sunday, March 30, at 7:00 a.m. CT / 12:00 UTC in Room N226.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...